NCT05570240

Brief Summary

The goal of this observational study is to learn about the association between pain characteristics and cognitive functions in chronic knee osteoarthritis. The main questions it aims to answer are:

  1. 1.If pain characteristics affect cognitive functions in severe knee OA patients?
  2. 2.If concentration of neuroinflammation mediators were raised in severe knee OA patients with comparing with control group participants?

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
60

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Aug 2019

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

August 7, 2019

Completed
1.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 21, 2021

Completed
1 day until next milestone

Study Completion

Last participant's last visit for all outcomes

April 22, 2021

Completed
1.5 years until next milestone

First Submitted

Initial submission to the registry

October 4, 2022

Completed
2 days until next milestone

First Posted

Study publicly available on registry

October 6, 2022

Completed
Last Updated

October 6, 2022

Status Verified

October 1, 2022

Enrollment Period

1.7 years

First QC Date

October 4, 2022

Last Update Submit

October 4, 2022

Conditions

Keywords

Chronic painKnee osteoarthritisCognitive deficits

Outcome Measures

Primary Outcomes (3)

  • The Western Ontario and McMaster universities Osteoarthritis Index (WOMAC)

    The WOMAC questionnaire has been used to assess subjects with OA of the hip or knee and consists of 24 items divided into 3 subscales: self-perception of pain (5 items), joint stiffness (2 items), and functional performance (17 items) during the previous 72 h.

    The WOMAC questionnaire were measured on the day before their surgery.

  • The cognitive abilities screening instrument (CASI)

    The CASI has been commonly used in dementia research and clinical practice to evaluate a subject's cognitive abilities.

    The CASI questionnaire were measured on the day before their surgery.

  • Glia mediators of neuroinflammation

    Glia mediators of neuroinflammation include interleukin-1β (IL-1β), interleukin-6 (IL-6), tumor necrosis factor α (TNF α), BDNF and fractalkine.

    All blood and CSF samples were obtained before spinal anesthesia.

Secondary Outcomes (1)

  • The geriatric depression scale (GDS-15)

    The GDS-15 questionnaire were measured on the day before their surgery.

Study Arms (2)

OA group

Knee osteoarthritis patients who were scheduled to receive elective total knee replacement surgery which need spinal anesthesia.

Control group

Control group patients were scheduled to receive elective general surgery or urological surgery with spinal anesthesia.

Eligibility Criteria

Age20 Years - 86 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

People with chronic knee osteoarthritis pain who will receive total knee replacement surgery. They have no other chronic pain except chronic knee pain. Furthermore they did not have any cerebral diseases such as stroke or brain tumor.

You may qualify if:

  • OA patients who were scheduled to receive elective surgery which need spinal anesthesia.
  • Age is more than 20 years old.
  • American Society of Anesthesiologists (ASA) class I-III.

You may not qualify if:

  • Unwilling to participate.
  • Age is lesser than 20 years old.
  • Autoimmune diseases.
  • Previous knee injury or infection history.
  • Brain region disease ex: stroke or brain tumor...etc.
  • Mild cognitive impairment, dementia or other neurodegenerative diseases.
  • Cancer.
  • With other chronic pain.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Kaohsiung Veterans General Hopital

Kaohsiung City, Zuoying Dist, 813414, Taiwan

Location

Related Publications (12)

  • Zhang Y, Jordan JM. Epidemiology of osteoarthritis. Clin Geriatr Med. 2010 Aug;26(3):355-69. doi: 10.1016/j.cger.2010.03.001.

  • Kyrkanides S, Tallents RH, Miller JN, Olschowka ME, Johnson R, Yang M, Olschowka JA, Brouxhon SM, O'Banion MK. Osteoarthritis accelerates and exacerbates Alzheimer's disease pathology in mice. J Neuroinflammation. 2011 Sep 7;8:112. doi: 10.1186/1742-2094-8-112.

  • Huang SW, Wang WT, Chou LC, Liao CD, Liou TH, Lin HW. Osteoarthritis increases the risk of dementia: a nationwide cohort study in Taiwan. Sci Rep. 2015 May 18;5:10145. doi: 10.1038/srep10145.

  • Li X, Tong Q, Gao J, Liu C; Alzheimer's Disease Neuroimaging Initiative; Liu Y. Osteoarthritis Was Associated With a Faster Decline in Hippocampal Volumes in Cognitively Normal Older People. Front Aging Neurosci. 2020 Aug 14;12:190. doi: 10.3389/fnagi.2020.00190. eCollection 2020.

  • Wu L, Wang X, Ye Y, Liu C. Association of Osteoarthritis With Changes in Structural Neuroimaging Markers Over Time Among Non-demented Older Adults. Front Aging Neurosci. 2021 Aug 10;13:664443. doi: 10.3389/fnagi.2021.664443. eCollection 2021.

  • Clark AK, Malcangio M. Fractalkine/CX3CR1 signaling during neuropathic pain. Front Cell Neurosci. 2014 May 7;8:121. doi: 10.3389/fncel.2014.00121. eCollection 2014.

  • Grace PM, Hutchinson MR, Maier SF, Watkins LR. Pathological pain and the neuroimmune interface. Nat Rev Immunol. 2014 Apr;14(4):217-31. doi: 10.1038/nri3621. Epub 2014 Feb 28.

  • Montague K, Malcangio M. The therapeutic potential of targeting chemokine signalling in the treatment of chronic pain. J Neurochem. 2017 May;141(4):520-531. doi: 10.1111/jnc.13927. Epub 2017 Feb 24.

  • Subbarayan MS, Joly-Amado A, Bickford PC, Nash KR. CX3CL1/CX3CR1 signaling targets for the treatment of neurodegenerative diseases. Pharmacol Ther. 2022 Mar;231:107989. doi: 10.1016/j.pharmthera.2021.107989. Epub 2021 Sep 4.

  • Cappoli N, Tabolacci E, Aceto P, Dello Russo C. The emerging role of the BDNF-TrkB signaling pathway in the modulation of pain perception. J Neuroimmunol. 2020 Dec 15;349:577406. doi: 10.1016/j.jneuroim.2020.577406. Epub 2020 Sep 24.

  • Malfait AM, Miller RE, Block JA. Targeting neurotrophic factors: Novel approaches to musculoskeletal pain. Pharmacol Ther. 2020 Jul;211:107553. doi: 10.1016/j.pharmthera.2020.107553. Epub 2020 Apr 18.

  • Tang J, Bair M, Descalzi G. Reactive Astrocytes: Critical Players in the Development of Chronic Pain. Front Psychiatry. 2021 May 28;12:682056. doi: 10.3389/fpsyt.2021.682056. eCollection 2021.

MeSH Terms

Conditions

Osteoarthritis, KneeChronic PainCognition Disorders

Condition Hierarchy (Ancestors)

OsteoarthritisArthritisJoint DiseasesMusculoskeletal DiseasesRheumatic DiseasesPainNeurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and SymptomsNeurocognitive DisordersMental Disorders

Study Officials

  • Chun-Hsien Wen, Physician

    Kaohsiung Veterans General Hospital.

    PRINCIPAL INVESTIGATOR
  • Chen-Hsiu Chen, Physician

    Kaohsiung Veterans General Hospital.

    STUDY DIRECTOR
  • Yuan-Yi Chia, Director

    Kaohsiung Veterans General Hospital.

    STUDY DIRECTOR
  • Chih-Chi Tsai, RA

    Kaohsiung Veterans General Hospital.

    STUDY CHAIR

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Physician

Study Record Dates

First Submitted

October 4, 2022

First Posted

October 6, 2022

Study Start

August 7, 2019

Primary Completion

April 21, 2021

Study Completion

April 22, 2021

Last Updated

October 6, 2022

Record last verified: 2022-10

Locations